Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Fundamental & Clinical Pharmacology

• Publication date

  2007-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1472-8206.2007.00532.xPMID 18001314
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism.

  2007cited by this paper
• Peroxisome Proliferator-Activated Receptor γ and Adipose Tissue—Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism

  2007cited by this paper
• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  2005cited by this paper
• A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial

  2005cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• Potential Role of Oral Thiazolidinedione Therapy in Preserving β-Cell Function in Type 2 Diabetes Mellitus

  2005cited by this paper
• Diabetic dyslipidaemia: insights for optimizing patient management

  2005cited by this paper
• Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects

  2004cited by this paper
• Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

  2004cited by this paper
• Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet.

  2004cited by this paper
• Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.

  2004cited by this paper
• Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

  2004cited by this paper
• Clinical interest of PPARs ligands.

  2004cited by this paper
• Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.

  2003cited by this paper
• EFFICACY AND SAFETY OF PIOGLITAZONE IN TYPE 2 DIABETES: A RANDOMISED, PLACEBO‐CONTROLLED STUDY IN PATIENTS RECEIVING STABLE INSULIN THERAPY

  2002cited by this paper
• Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus

  2002cited by this paper
• Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

  2002cited by this paper
• Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

  2001cited by this paper
• Homocysteinemia in patients with type 1 diabetes in relation to renal function.

  2001cited by this paper
• A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

  2001cited by this paper
• The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

  2001cited by this paper
• Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients

  2000cited by this paper
• Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.

  2000cited by this paper
• Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

  2000cited by this paper
• Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

  2000cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes

  1999cited by this paper

• Prevention of Liver Damage in Rats by Artichoke Leaf Extract, Colchicine and Pioglitazone

  2025cites this paper
• Small dense low-density lipoprotein-lowering agents

  2019cites this paper
• Hydrochloride pioglitazone protects diabetic rats against podocyte injury through preserving glomerular podocalyxin expression.

  2014cites this paper
• Low HDL-cholesterol: a strong predictor of glycemic response to glitazone treatment in patients with type 2 diabetes.

  2011cites this paper
• Unraveling pancreatic islet biology by quantitative proteomics

  2011cites this paper
• The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis.

  2010cites this paper
• Efecto de la combinación rosiglitazona/metformin y de la monoterapia con metformin sobre los componentes del síndrome metabólico

  2008cites this paper